ChEBI: S-adenosyl-L-methionine is a sulfonium compound that is the S-adenosyl derivative of L-methionine. It is an intermediate in the metabolic pathway of methionine. It has a role as a coenzyme, a nutraceutical, a micronutrient, a human metabolite, a Saccharomyces cerevisiae metabolite, a Mycoplasma genitalium metabolite and a cofactor. It is a conjugate acid of a S-adenosyl-L-methioninate. It is an enantiomer of a S-adenosyl-D-methionine. It is a tautomer of a S-adenosyl-L-methionine zwitterion.
Veterinary Drugs and Treatments
In small animal medicine, SAMe is most commonly used as an adjunctive
treatment for liver disease (chronic hepatitis, hepatic lipidosis,
cholangiohepatitis, feline triad disease, etc.). It may also be of
benefit in osteoarthritis, treatment of acute hepatotoxin-induced
liver toxicity (e.g., acetaminophen toxicity), and at-risk patients on
long-term therapy using drugs with hepatotoxic potential.
In humans, SAMe is being used as a treatment for depression,
osteoarthritis, AIDS-related myopathy, intrahepatic cholestasis,
liver disease, alcoholic liver cirrhosis, fibromyalgia, adult ADHD,
Alzheimer’s, migraines, etc.
